Surrogate endpoints of efficacy

Surrogate endpoints of efficacy

Show other versions (2)
Saved in:
Bibliographic Details
Other Authors: Markman, Maurie (Speaker)
Format: Electronic Video
Language:English
Published: London : Henry Stewart Talks, 2018.
Series:Henry Stewart talks. Biomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity.
Subjects:
Antineoplastic agents.
Cancer > Chemotherapy.
Cancer > Treatment > Evaluation.
Clinical trials.
Outcome assessment (Medical care).
Antineoplastic Agents > administration & dosage.
Antineoplastic Agents > therapeutic use.
Biomarkers.
Clinical Trials as Topic.
Endpoint Determination.
Goals.
Neoplasms > prevention & control.
Neoplasms > therapy.
Treatment Outcome.
Online Access:https://hstalks.com/bs/1117/
Series
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000cgm a2200000 a 4500
001 HST2040_1_2
003 UkLoHST
006 m c
007 cr|cna|||a||||
007 vz|czazum
008 181015s2018 enk|||||||||||s|||v|eng d
028 5 0 |a 2040  |b Henry Stewart Talks 
035 |a (UkLoHST)1117 
040 |a UkLoHST  |b eng  |c UkLoHST 
100 1 |a Markman, Maurie.  |4 spk 
245 1 0 |a Surrogate endpoints of efficacy  |h [electronic resource] /  |c Maurie Markman. 
260 |a London :  |b Henry Stewart Talks,  |c 2018. 
300 |a 1 online resource (1 streaming video file (33 min.) :  |b color, sound). 
490 1 |a Cancer therapy : latest thinking in efficacy and toxicity,  |x 2056-452X 
500 |a Animated audio-visual presentation with synchronized narration. 
500 |a Revised version of a talk first published in 2009. 
500 |a Title from title frames. 
505 0 |a Contents: Improvement in overall survival must be considered the single most important goal of any new antineoplastic strategy -- Also increasingly recognized that in well-defined settings it is reasonable to employ other objectively measurable endpoints of efficacy such as time to symptomatic disease progression -- The rationale for the use of surrogate or alternative endpoints in cancer clinical trials -- Examples of where such endpoints may be appropriately utilized. 
506 |a Access restricted to subscribers. 
538 |a Mode of access: World Wide Web. 
650 0 |a Antineoplastic agents. 
650 0 |a Cancer  |x Chemotherapy. 
650 0 |a Cancer  |x Treatment  |x Evaluation. 
650 0 |a Clinical trials. 
650 0 |a Outcome assessment (Medical care). 
650 2 |a Antineoplastic Agents  |x administration & dosage. 
650 2 |a Antineoplastic Agents  |x therapeutic use. 
650 2 |a Biomarkers. 
650 2 |a Clinical Trials as Topic. 
650 2 |a Endpoint Determination. 
650 2 |a Goals. 
650 2 |a Neoplasms  |x prevention & control. 
650 2 |a Neoplasms  |x therapy. 
650 2 |a Treatment Outcome. 
830 0 |a Henry Stewart talks.  |p Biomedical & life sciences collection.  |p Cancer therapy : latest thinking in efficacy and toxicity. 
856 4 0 |u https://hstalks.com/bs/1117/ 
856 4 2 |u https://hstalks.com/bs/p/385/  |3 Series 
999 |c 200479  |d 200479 

Similar Items